Hypoxia-inducible factor underlies von Hippel-Lindau disease stigmata
- PMID: 36040300
- PMCID: PMC9427099
- DOI: 10.7554/eLife.80774
Hypoxia-inducible factor underlies von Hippel-Lindau disease stigmata
Abstract
von Hippel-Lindau (VHL) disease is a rare hereditary cancer syndrome that causes a predisposition to renal clear-cell carcinoma, hemangioblastoma, pheochromocytoma, and autosomal-recessive familial polycythemia. pVHL is the substrate conferring subunit of an E3 ubiquitin ligase complex that binds to the three hypoxia-inducible factor alpha subunits (HIF1-3α) for polyubiquitylation under conditions of normoxia, targeting them for immediate degradation by the proteasome. Certain mutations in pVHL have been determined to be causative of VHL disease through the disruption of HIFα degradation. However, it remains a focus of investigation and debate whether the disruption of HIFα degradation alone is sufficient to explain the complex genotype-phenotype relationship of VHL disease or whether the other lesser or yet characterized substrates and functions of pVHL impact the development of the VHL disease stigmata; the elucidation of which would have a significant ramification to the direction of research efforts and future management and care of VHL patients and for those manifesting sporadic counterparts of VHL disease. Here, we examine the current literature including the other emergent pseudohypoxic diseases and propose that the VHL disease-phenotypic spectrum could be explained solely by the varied disruption of HIFα signaling upon the loss or mutation in pVHL.
Keywords: HIF; PHD; VHL; cancer biology; hypoxia; oxygen-sensing; pseudohypoxic diseases.
© 2022, Ohh et al.
Conflict of interest statement
MO, CT, FF, DT No competing interests declared
Figures


Similar articles
-
Contrasting effects on HIF-1alpha regulation by disease-causing pVHL mutations correlate with patterns of tumourigenesis in von Hippel-Lindau disease.Hum Mol Genet. 2001 May 1;10(10):1029-38. doi: 10.1093/hmg/10.10.1029. Hum Mol Genet. 2001. PMID: 11331613
-
Identification of cyclin D1 and other novel targets for the von Hippel-Lindau tumor suppressor gene by expression array analysis and investigation of cyclin D1 genotype as a modifier in von Hippel-Lindau disease.Cancer Res. 2002 Jul 1;62(13):3803-11. Cancer Res. 2002. PMID: 12097293
-
von Hippel-Lindau protein mutants linked to type 2C VHL disease preserve the ability to downregulate HIF.Hum Mol Genet. 2001 May 1;10(10):1019-27. doi: 10.1093/hmg/10.10.1019. Hum Mol Genet. 2001. PMID: 11331612
-
Role of VHL gene mutation in human cancer.J Clin Oncol. 2004 Dec 15;22(24):4991-5004. doi: 10.1200/JCO.2004.05.061. J Clin Oncol. 2004. PMID: 15611513 Review.
-
The HIF and other quandaries in VHL disease.Oncogene. 2018 Jan 11;37(2):139-147. doi: 10.1038/onc.2017.338. Epub 2017 Sep 18. Oncogene. 2018. PMID: 28925400 Review.
Cited by
-
While paradigms shift in von Hippel-Lindau management, questions remain in optimal multidisciplinary neuro-oncology care.Neuro Oncol. 2023 May 4;25(5):839-840. doi: 10.1093/neuonc/noad049. Neuro Oncol. 2023. PMID: 36869778 Free PMC article. No abstract available.
-
Identification of gene signatures related to hypoxia and angiogenesis in pancreatic cancer to aid immunotherapy and prognosis.Front Oncol. 2023 Mar 30;13:1119763. doi: 10.3389/fonc.2023.1119763. eCollection 2023. Front Oncol. 2023. PMID: 37064125 Free PMC article.
-
Conformational fluidity of intrinsically disordered proteins in crowded environment: a molecular dynamics simulation study.J Biomol Struct Dyn. 2024 Sep 16:1-13. doi: 10.1080/07391102.2024.2404531. Online ahead of print. J Biomol Struct Dyn. 2024. PMID: 39285530
-
Belzutifan-induced regression of retinal capillary hemangioblastoma: A case-series.Am J Ophthalmol Case Rep. 2024 Feb 10;33:102011. doi: 10.1016/j.ajoc.2024.102011. eCollection 2024 Mar. Am J Ophthalmol Case Rep. 2024. PMID: 38374949 Free PMC article.
-
Glucose deprivation impairs hypoxia-inducible factor-1α synthesis.Discov Oncol. 2024 Oct 28;15(1):595. doi: 10.1007/s12672-024-01484-1. Discov Oncol. 2024. PMID: 39466364 Free PMC article.
References
-
- Appelhoff RJ, Tian YM, Raval RR, Turley H, Harris AL, Pugh CW, Ratcliffe PJ, Gleadle JM. Differential function of the prolyl hydroxylases PHD1, PHD2, and PHD3 in the regulation of hypoxia-inducible factor. The Journal of Biological Chemistry. 2004;279:38458–38465. doi: 10.1074/jbc.M406026200. - DOI - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical